six-minute walking distance

MDA 2023: Data support AT-GAA’s long-term benefits for LOPD patients

After two years being treated with AT-GAA (cipaglucosidase alfa/miglustat), adults with late-onset Pompe disease (LOPD) maintained their improvements in walking ability and had stabilized breathing function, as well as a reduction in the levels of disease biomarkers, according to…

6MWT With LOPD Patients May Depend Most on Age, Walker Use

Age and the use of an assistive device like a walker may tell how well a patient with late-onset Pompe disease will do in a six-minute walk test (6MWT), a small study suggests. The 6MWT is considered a gold standard for determining, through difficulties in walking, the severity of…

6MWD Test Reliable Measure of Motor Decline in LOPD, Study Finds

The six-minute walk distance (6MWD) test is a reliable measure of declines in motor abilities in people with late-onset Pompe disease (LOPD), a two-year study that evaluated a series of such tests reported. Other common measures of motor function and muscle strength failed to reliably detect such changes in…